Prospective Grant of Exclusive License: The Catalytic Moiety of the Glucose-6-Phosphatase System: The Gene and Protein and Related Mutations, 14601-14602 [E7-5672]

Download as PDF Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices Dated: March 20, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1508 Filed 3–27–07; 8:45 am] DATES: BILLING CODE 4140–01–M ADDRESSES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2007 will be considered. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Technologies Relating to SH2 Domain Binding Inhibitors and Inhibition of Cell Motility and Angiogenesis National Institutes of Health, Public Health Service, HHS. ACTION: Notice. sroberts on PROD1PC70 with NOTICES AGENCY: 17:09 Mar 27, 2007 Jkt 211001 These technologies relate to anti-cancer drugs that target the inhibition of specific enzymes in certain pathways that will interfere with a cell’s signal transduction processes. The current technologies include specific compounds that inhibit GRB2 SH2 domain binding. In addition, the technologies relate to how these compounds may inhibit cell motility and angiogenesis. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 09/937,150, filed March 26, 2002, entitled ‘‘Phenylalanine Derivatives’’ [E–105–1999/0–US–07]; U.S. Patent Application No. 10/517,717, filed March 17, 2005, entitled ‘‘SH2 Domain Binding Inhibitors’’ [E–262–2000/1–US–03]; U.S. Patent Application No. 10/944,699, filed September 17, 2004, entitled ‘‘SH2 Domain Binding Inhibitors’’ [E–315– 2003/0–US–02]; PCT Patent Application PCT/US05/35246, filed September 30, 2005, entitled ‘‘A New Approach Toward Macrocyclization of Peptides’’ [E–327–2004/0–PCT–02]; U.S. Provisional Patent Application No. 60/ 867,307, filed November 27, 2006, entitled ‘‘Macrocyclic GRB2 SH2 Domain Binding Inhibitors Prepared Using Achiral Alkenyl Amines’’ [E– 305–2006/0–US–01]; U.S. Patent 6,977,241, issued December 20, 2005, entitled ‘‘SH2 Domain Binding Inhibitors’’ [E–262–2000/0–US–03]; U.S. Patent 7,132,392, issued November 11, 2006, entitled ‘‘Inhibition of Cell Motility and Angiogenesis by Inhibitors of the GRB2 SH2 Domain’’ [E–265– 1999/0–US–07]; to Angion Biomedica Corporation, having a place of business in Manhasset, New York. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to cancer and the modulation of angiogenesis in inflammatory disease. VerDate Aug<31>2005 Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Adaku Nwachukwu, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5560; Facsimile: (301) 402–0220; E-mail: madua@mail.nih.gov. Dated: March 16, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–5674 Filed 3–27–07; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 14601 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: The Catalytic Moiety of the Glucose-6-Phosphatase System: The Gene and Protein and Related Mutations National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in U.S. Patent Number 5,460,942 issued October 24, 1995 entitled, ‘‘The Catalytic Moiety of the Glucose-6-Phosphatase System: the Gene and Protein and Related Mutations’’ (HHS Ref. No. E–179–1993/ 0–US–01) to GlyGenix, Inc., having a place of business in Cheshire, CT 06410. The contemplated exclusive license may be limited to the following field of use: an FDA-approvable human therapeutic for Glycogen Storage Disease Type Ia. The United States of America is the assignee of the patent rights in this invention. DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2007 will be considered. ADDRESSES: Requests for a copy of the patent, inquiries, comments, and other materials relating to the contemplated license should be directed to: Tara L. Kirby, PhD, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: 301–435–4426; Facsimile: 301–402– 0220; E-mail: kirbyt@mail.nih.gov. SUPPLEMENTARY INFORMATION: Glycogen storage diseases result from at least 10 different genetic defects in proteins required by glycogen metabolism. Glycogen storage disease Type Ia (GSD, also known as von Gierke disease) is defined as the deficiency of glucose-6phosphatase (G–6–Pase) which is normally present in liver, kidney, and intestine. Glycogen storage disease Type la is inherited by one per 100,000 people as an autosomal recessive trait and is usually manifested during the first twelve months of life by symptomatic hypoglycemia, or by the recognition of hepatomegaly. In E:\FR\FM\28MRN1.SGM 28MRN1 14602 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices addition, GSD type Ia can cause growth retardation, delayed adolescence, lacticacidemia, hyperlipidemia, hyperuricemia, and in adults, hepatic adenomas. The invention discloses nucleic acid sequences and vectors useful for producing recombinant G–6–Pase proteins, as well as nucleic acid sequences and kits for detecting a mutation in the G–6–Pase gene. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: March 20, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–5672 Filed 3–27–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Bureau of Customs and Border Protection, Department of Homeland Security. ACTION: Notice of re-approval The Strawn Group of Houston, Texas, as a commercial gauger. AGENCY: Re-Accreditation of Core Laboratories, Inc., as a Commercial Laboratory Bureau of Customs and Border Protection, Department of Homeland Security. ACTION: Notice of re-accreditation of Core Laboratories, Inc. of Sulfur, Louisiana, as an accredited commercial laboratory. AGENCY: SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.12, Core Laboratories, Inc., 4025 Oak Lane, Sulfur, Louisiana 60665, has been reaccredited to test Petroleum and Petroleum Products entered under Chapters 17 and 29 of the Harmonized Tariff Schedule of the United States Jkt 211001 Protection to conduct the specific gauger service requested. Alternatively, inquiries regarding the specific gauger services this entity is approved to perform may be directed to the Bureau of Customs and Border Protection by calling (202) 344–1060. The inquiry may also be sent to https://www.cbp.gov/xp/ cgov/import/operations_support/ labs_scientific_svcs/ org_and_operations.xml. DATES: The re-approval of The Strawn Group as a commercial gauger became effective on January 4, 2005. The next triennial inspection date will be scheduled for January 2008. FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, PhD, or Randall Breaux, Laboratories and Scientific Services, Bureau of Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202–344–1060. Dated: March 22, 2007. Ira S. Reese, Executive Director, Laboratories and Scientific Services. [FR Doc. E7–5706 Filed 3–27–07; 8:45 am] BILLING CODE 9111–14–P DEPARTMENT OF HOMELAND SECURITY Bureau of Customs and Border Protection [CBP Dec. 07–13] Re-Approval of the Strawn Group as a Commercial Gauger [CBP Dec. 07–11] sroberts on PROD1PC70 with NOTICES BILLING CODE 9111–14–P [CBP Dec. 07–12] Bureau of Customs and Border Protection 17:09 Mar 27, 2007 Dated: March 22, 2007. Ira S. Reese, Executive Director, Laboratories and Scientific Services. [FR Doc. E7–5705 Filed 3–27–07; 8:45 am] Bureau of Customs and Border Protection DEPARTMENT OF HOMELAND SECURITY VerDate Aug<31>2005 (HTSUS) for customs purposes, in accordance with the provisions of 19 CFR 151.12. Anyone wishing to employ this entity to conduct laboratory analysis should request and receive written assurances from the entity that it is accredited or approved by the Bureau of Customs and Border Protection to conduct the specific test requested. Alternatively, inquiries regarding the specific tests this entity is accredited to perform may be directed to the Bureau of Customs and Border Protection by calling (202) 344–1060. The inquiry may also be sent to https://www.cbp.gov/xp/ cgov/import/ operations_support/labs_scientific_svcs/ org_and_operations.xml. DATES: The re-accreditation of Core Laboratories, Inc., as an accredited laboratory became effective on March 23, 2005. The next triennial inspection date will be scheduled for March 2008. FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, PhD, or Randall Breaux, Laboratories and Scientific Services, Bureau of Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202–344–1060. SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.13, The Strawn Group, 3855 Villa Ridge, Houston, Texas 77068, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils for customs purposes, in accordance with the provisions of 19 CFR 151.13. Anyone wishing to employ this entity for gauger services should request and receive written assurances from the entity that it is approved by the Bureau of Customs and Border PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 Re-Accreditation and Re-Approval of Amspec Services as a Commercial Gauger and Laboratory Bureau of Customs and Border Protection, Department of Homeland Security. ACTION: Notice of re-approval of Amspec Services of Wilmington, North Carolina, as a commercial gauger and laboratory. AGENCY: SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.12 and 151.13, Amspec Services, 2841 Carolina Beach Road, Suite 3B, Wilmington, North Carolina 28412, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils, and to test petroleum and petroleum products for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 151.13. Anyone wishing to employ this entity to conduct laboratory analysis or gauger services should request and receive written assurances from the entity that it is accredited or approved by the Bureau of Customs and Border Protection to conduct the specific test or gauger service requested. Alternatively, E:\FR\FM\28MRN1.SGM 28MRN1

Agencies

[Federal Register Volume 72, Number 59 (Wednesday, March 28, 2007)]
[Notices]
[Pages 14601-14602]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-5672]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: The Catalytic Moiety of 
the Glucose-6-Phosphatase System: The Gene and Protein and Related 
Mutations

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in 
U.S. Patent Number 5,460,942 issued October 24, 1995 entitled, ``The 
Catalytic Moiety of the Glucose-6-Phosphatase System: the Gene and 
Protein and Related Mutations'' (HHS Ref. No. E-179-1993/0-US-01) to 
GlyGenix, Inc., having a place of business in Cheshire, CT 06410. The 
contemplated exclusive license may be limited to the following field of 
use: an FDA-approvable human therapeutic for Glycogen Storage Disease 
Type Ia. The United States of America is the assignee of the patent 
rights in this invention.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before May 29, 
2007 will be considered.

ADDRESSES: Requests for a copy of the patent, inquiries, comments, and 
other materials relating to the contemplated license should be directed 
to: Tara L. Kirby, PhD, Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 301-435-
4426; Facsimile: 301-402-0220; E-mail: kirbyt@mail.nih.gov.

SUPPLEMENTARY INFORMATION: Glycogen storage diseases result from at 
least 10 different genetic defects in proteins required by glycogen 
metabolism. Glycogen storage disease Type Ia (GSD, also known as von 
Gierke disease) is defined as the deficiency of glucose-6-phosphatase 
(G-6-Pase) which is normally present in liver, kidney, and intestine. 
Glycogen storage disease Type la is inherited by one per 100,000 people 
as an autosomal recessive trait and is usually manifested during the 
first twelve months of life by symptomatic hypoglycemia, or by the 
recognition of hepatomegaly. In

[[Page 14602]]

addition, GSD type Ia can cause growth retardation, delayed 
adolescence, lacticacidemia, hyperlipidemia, hyperuricemia, and in 
adults, hepatic adenomas.
    The invention discloses nucleic acid sequences and vectors useful 
for producing recombinant G-6-Pase proteins, as well as nucleic acid 
sequences and kits for detecting a mutation in the G-6-Pase gene.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, the NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 20, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E7-5672 Filed 3-27-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.